Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
about
Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycleTargeting glycogen metabolism in bladder cancerEffect of P-glycoprotein on flavopiridol sensitivityFlavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosisAnalysing the Effect of Mutation on Protein Function and Discovering Potential Inhibitors of CDK4: Molecular Modelling and Dynamics StudiesBcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient.Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Anticancer drug targets: cell cycle and checkpoint control.Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.Small molecule modulators of cyclin-dependent kinases for cancer therapy.Cyclin D1 downregulation is important for permanent cell cycle exit and initiation of differentiation induced by anchorage-deprivation in human keratinocytes.Anticancer Alkaloids from Trees: Development into Drugs.Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.Pharmacological treatments for prostate cancer.Small-molecule cyclin-dependent kinase modulators.Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2Cyclin Dependent Kinase 9 Inhibitors for Cancer TherapyFinal results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer.A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7.Emerging drug profile: cyclin-dependent kinase inhibitorsRole of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesEnhancement of radiation effects by flavopiridol in uterine cervix cancer cells.Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvaePhase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseStructural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.Cell cycle proteins as promising targets in cancer therapyMixed lineage leukemia: roles in human malignancies and potential therapy.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.The CDK inhibitors in cancer research and therapy.Molecular targeted agents for gastric and gastroesophageal junction cancer.Cyclin-dependent kinase modulators and cancer therapy.Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development.Site-specific anticancer effects of dietary flavonoid quercetin.
P2860
Q24299947-7A83B965-9F4F-4FBD-AEFB-F7F0F8DE91A5Q27025144-B1A6BBA3-BE2B-48DF-AA78-BA2400B5F31DQ28365275-5524435D-7DB1-4036-BF3F-22CEA0F6D2CEQ28369193-92F23CDD-9A4B-4401-8785-77E91A6F6BB6Q28547120-E4B94E02-232E-484A-B327-C6D9EEFE6604Q31407508-F2197F2C-F37E-4C2F-BD0D-C3A522985428Q33264498-843F1352-DE46-4E40-89BB-83FC94E474BAQ33387187-C440537E-CAB8-4958-B458-962BE9EF87B9Q33583509-C1FF3A7A-F578-4B59-9B77-D837E4259238Q33627721-D9535770-D326-4B4F-8AA1-3F744616B32AQ33801116-5E5D868D-5E2B-4F61-8A1A-EFFC699F31D1Q33952759-998E373A-327F-4F16-97B7-125CA5DC6F6AQ33968055-CA7BB107-38CE-4FC0-8F7B-90416E33E039Q34293568-925DF123-BE49-4ED0-A5CC-7D42739ECEF7Q34331020-8E1456FA-12A4-4593-9E6F-0B7ED8CFC164Q34549113-8749F7C7-08F7-4D52-82CC-F2619028F07CQ34615632-DE6FDFEA-FDCC-41AF-B80E-96336543B540Q35011889-692D48D9-BD6C-45EA-ADF2-5EFC1B769CB0Q35551149-52A31470-D4DD-48D5-92BC-47DE86ABC41BQ35722786-270DE051-EA48-4252-B87B-EAAAA09B48E3Q36015334-CDD6B4F9-2A91-41A0-92F1-484B45B0793EQ36019515-858B249E-93F0-428E-8AE7-CA3F2CB9DEBAQ36379379-B473E9F0-AFFD-4211-94D5-835F40FEEB04Q36498926-C56B61E9-5033-45C6-8729-74EF2182C403Q36505765-72B3D504-54BD-4A39-A438-7B98611AD4AEQ37185372-F18A71C6-E143-4973-863E-CFC98F589462Q37226511-2696868A-8A70-4BD1-B5FC-2456AC94D052Q37447008-BCCE42FA-C9CE-4E43-86E6-0966798FE30EQ37467587-1AD2F914-E344-4042-B44B-23596AD9437BQ37474415-546B1697-6F49-4B43-A9F2-8BA1A3371CF5Q37672900-E9B8ED80-ABD4-44F5-AE8F-0B6C8F060158Q37693690-C066BF4B-83BB-4985-894A-BA43F6A62282Q37710708-75CB5CA9-6ACA-44FB-B069-1D0D64F44875Q37767703-16072EA9-D85F-418D-9DC9-597D1CD0AD00Q37798827-5E1D7DFC-2758-4587-A557-C4C647E7FAFEQ37923861-47CAB908-9346-459A-A3AC-80F813086C2EQ37962816-9B7B9E63-EDBE-4771-989F-595F51E66A3AQ38038670-034365A9-1A13-4782-BEF5-117CE340B216Q38088759-F5A9B2FC-AEC7-47DC-9C0C-5FD6159BB074Q38174655-5F21279A-59AE-49DC-BFF8-3A6FC5AF6BEA
P2860
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@ast
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@en
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@nl
type
label
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@ast
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@en
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@nl
prefLabel
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@ast
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@en
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@nl
P2093
P3181
P356
P1476
Growth inhibition with reversi ...... noma cells by flavone L86-8275
@en
P2093
E Sausville
H Sedlacek
M Stetler-Stevenson
P304
P3181
P356
10.1093/JNCI/84.22.1736
P407
P577
1992-11-18T00:00:00Z